Incidence of ocular sequelae post-HAART treatment
| Sequelae | Overall (n=90) | IR+IRU (n=26) | IR (n=39) | IF (n=25) | p Value |
|---|---|---|---|---|---|
| HAART = highly active antiretroviral therapy; CMO = cystoid macular oedema; ERM = epiretinal membrane; RD = retinal detachment; IR+IRU = immune recovery with immune recovery uveitis; IR = immune recovery without immune recovery uveitis; IF = immune failure. | |||||
| *p Values obtained from Cox regression analysis with immune recovery status as a time dependent covariate. | |||||
| †Excluded six eyes with cataracts at the baseline visit. | |||||
| ‡p Values from Fisher’s exact test. | |||||
| CMO | 22 (24%) | 18 (69%) | 2 (5%) | 2 (8%) | 0.06* |
| ERM | 27 (30%) | 17 (65%) | 6 (15%) | 4 (16%) | 0.05* |
| RD | 13 (14%) | 5 (19%) | 3 (8%) | 5 (20%) | 0.35* |
| Cataract† | 47/84 (52%) | 21/25 (84%) | 12/37 (33%) | 14/22 (64%) | <0.001‡ |